Abstract
Introduction Historically, Candida glabrata has been viewed as a relatively nonpathogenie saprophyte of the normal flora of healthy individuals. It is now considered a prominent fungal pathogen, largely due to the widespread use of immunosuppressive therapy, together with broad-spectrum antimycotic therapy (reviewed in reference I). C. glabrata infections can be mucosal or systemic and are common in unhealthy hosts (e.g., immunocompromised or diabetic) (reviewed in reference 1). Furthermore, these infections are difficult to treat and are often resistant to many azole antifungal agents. Unfortunately, investigations of C. glabrata infection have been relatively few compared with those of other Candida species, accounting for only a small percentage of published studies on medically important fungal infections. This review will briefly discuss the biology, epidemiology, and pathogenesis of C. glabrata infections, followed by a more detailed discussion of the clinical spectrum of disease, including management and antiRmga1 resistance.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
